{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T18:24:21Z","timestamp":1780683861797,"version":"3.54.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Alzheimer\u2019s disease (AD) clinical trials enroll participants at various site types including research-focused academic institutions and independent non-academic sites. Limited research has examined the impact of site type on recruitment and retention outcomes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>To evaluate potential differences between site types, we used data from the Anti-Amyloid Treatment for Asymptomatic AD (A4) trial, the largest completed preclinical AD trial to date. We first compared the frequency of varying recruitment sources between site types. We then examined potential differences in participant- and site-level characteristics. To assess potential site type differences in retention, we fit a multivariable logistic regression model adjusting for variables associated with site type. For participants who prematurely discontinued, we examined potential differences by site type in reasons for dropout.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>One thousand and fifty-eight participants were randomized at 50 academic (<jats:italic>N<\/jats:italic>\u2009=\u2009835) and 15 non-academic (<jats:italic>N<\/jats:italic>\u2009=\u2009223) sites in North America. Academic sites had higher proportions of participants recruited through earned media and organizational referrals and lower proportions recruited through internal referrals and advertisements, compared to non-academic sites. Participant-level characteristics differed between site types. Compared to non-academic sites, academic sites had higher proportions of participants with a family history of dementia and a professional degree (highest education category), but lower proportions of individuals with a history of diabetes, a CDR-SB score above 0, and belonging to a racial and ethnic underrepresented group. Though the results were not statistically significant, non-academic sites had a higher screening rate (number of participants screened\/site\/month), but a lower randomization rate (randomized\/screened) compared to academic sites. No site type differences in completion rates were observed. When examining reasons for discontinuation, we found that among the 72 participants who discontinued the trial at non-academic sites, 56 (77.8%) withdrew consent or were lost to follow up. In contrast, 140 out of 243 (57.6%) participants who discontinued the trial in academic sites withdrew consent or were lost to follow up.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Our findings shed light on important site type differences that investigators should consider when making choices around site, design, and conduct in multisite preclinical AD trials.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13195-025-01867-8","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T13:04:41Z","timestamp":1760447081000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Recruitment and retention in a preclinical AD trial: comparisons between academic and non-academic sites"],"prefix":"10.1186","volume":"17","author":[{"given":"Marina","family":"Ritchie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kedir","family":"Hussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Langford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zara","family":"Kotadiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Donohue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Aisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reisa A.","family":"Sperling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Grill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rema","family":"Raman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"key":"1867_CR1","doi-asserted-by":"crossref","unstructured":"Friedman LM, Furberg CD, Demets DL, Reboussin DM, Granger CB. Multicenter trials. Springer International Publishing; 2015. pp. 501\u201318.","DOI":"10.1007\/978-3-319-18539-2_21"},{"issue":"2","key":"1867_CR2","doi-asserted-by":"publisher","first-page":"e059230","DOI":"10.1136\/bmjopen-2021-059230","volume":"12","author":"RM Jacques","year":"2022","unstructured":"Jacques RM, Ahmed R, Harper J, Ranjan A, Saeed I, Simpson RM, et al. Recruitment, consent and retention of participants in randomised controlled trials: a review of trials published in the National Institute for health research (NIHR) journals library (1997\u20132020). BMJ Open. 2022;12(2):e059230.","journal-title":"BMJ Open"},{"issue":"1","key":"1867_CR3","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1177\/1740774514558307","volume":"12","author":"B Carlisle","year":"2015","unstructured":"Carlisle B, Kimmelman J, Ramsay T, Mackinnon N. Unsuccessful trial accrual and human subjects protections: an empirical analysis of recently closed trials. Clin Trails. 2015;12(1):77\u201383.","journal-title":"Clin Trails"},{"key":"1867_CR4","doi-asserted-by":"crossref","unstructured":"Bernardez-Pereira S, Lopes RD, Carrion MJM, Santucci EV, Soares RM, De Oliveira Abreu M et al. Prevalence, characteristics, and predictors of early termination of cardiovascular clinical trials due to low recruitment: Insights from the ClinicalTrials.gov registry. American Heart Journal. 2014;168(2):213-9.e1.","DOI":"10.1016\/j.ahj.2014.04.013"},{"issue":"10","key":"1867_CR5","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1001\/jama.2014.1361","volume":"311","author":"B Kasenda","year":"2014","unstructured":"Kasenda B, Von Elm E, You J, Bl\u00fcmle A, Tomonaga Y, Saccilotto R, et al. Prevalence, characteristics, and publication of discontinued randomized trials. JAMA. 2014;311(10):1045.","journal-title":"JAMA"},{"issue":"14","key":"1867_CR6","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1056\/NEJMsr1203730","volume":"367","author":"RJ Little","year":"2012","unstructured":"Little RJ, D\u2019Agostino R, Cohen ML, Dickersin K, Emerson SS, Farrar JT, et al. The prevention and treatment of missing data in clinical trials. N Engl J Med. 2012;367(14):1355\u201360.","journal-title":"N Engl J Med"},{"key":"1867_CR7","unstructured":"Edlund W, Gronseth G, So Y, Franklin G. Clinical practice guideline process manual. American Academy of Neurology; 2004."},{"key":"1867_CR8","doi-asserted-by":"crossref","unstructured":"Ritchie M, Gillen DL, Grill JD. Recruitment across two decades of NIH-funded alzheimer\u2019s disease clinical trials. Alzheimers Res Ther. 2023;15(1).","DOI":"10.1186\/s13195-023-01177-x"},{"key":"1867_CR9","doi-asserted-by":"crossref","unstructured":"Ritchie M, Gillen DL, Grill JD. Estimating attrition in mild-to-moderate alzheimer\u2019s disease and mild cognitive impairment clinical trials. Alzheimers Res Ther. 2023;15(1).","DOI":"10.1186\/s13195-023-01352-0"},{"issue":"12","key":"1867_CR10","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1056\/NEJMoa2305032","volume":"389","author":"RA Sperling","year":"2023","unstructured":"Sperling RA, Donohue MC, Raman R, Rafii MS, Johnson K, Masters CL, et al. Trial of Solanezumab in preclinical alzheimer\u2019s disease. N Engl J Med. 2023;389(12):1096\u2013107.","journal-title":"N Engl J Med"},{"key":"1867_CR11","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.neurobiolaging.2015.11.007","volume":"39","author":"JD Grill","year":"2016","unstructured":"Grill JD, Zhou Y, Elashoff D, Karlawish J. Disclosure of amyloid status is not a barrier to recruitment in preclinical alzheimer\u2019s disease clinical trials. Neurobiol Aging. 2016;39:147\u201353.","journal-title":"Neurobiol Aging"},{"key":"1867_CR12","doi-asserted-by":"crossref","unstructured":"2025 Alzheimer\u2019s disease facts and figures. Alzheimer\u2019s & Dementia. 2025;21(4).","DOI":"10.1002\/alz.70235"},{"issue":"10","key":"1867_CR13","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S1474-4422(13)70194-7","volume":"12","author":"SJ Vos","year":"2013","unstructured":"Vos SJ, Xiong C, Visser PJ, Jasielec MS, Hassenstab J, Grant EA, et al. Preclinical alzheimer\u2019s disease and its outcome: a longitudinal cohort study. Lancet Neurol. 2013;12(10):957\u201365.","journal-title":"Lancet Neurol"},{"issue":"3","key":"1867_CR14","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.neuron.2014.10.038","volume":"84","author":"R Sperling","year":"2014","unstructured":"Sperling R, Mormino E, Johnson K. The evolution of preclinical alzheimer\u2019s disease: implications for prevention trials. Neuron. 2014;84(3):608\u201322.","journal-title":"Neuron"},{"issue":"2","key":"1867_CR15","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1097\/WAD.0b013e3181c9983f","volume":"24","author":"SD Edland","year":"2010","unstructured":"Edland SD, Emond JA, Aisen PS, Petersen RC. NIA-Funded alzheimer centers are more efficient than commercial clinical recruitment sites for conducting secondary prevention trials of dementia. Alzheimer Disease Assoc Disorders. 2010;24(2):159\u201364.","journal-title":"Alzheimer Disease Assoc Disorders"},{"issue":"4","key":"1867_CR16","doi-asserted-by":"publisher","first-page":"874","DOI":"10.14283\/jpad.2024.136","volume":"11","author":"R Raman","year":"2024","unstructured":"Raman R, Hussen K, Donohue MC, Ernstrom K, Holdridge KC, Langford O, et al. Pre-Randomization predictors of study discontinuation in a preclinical alzheimer\u2019s disease randomized controlled trial. J Prev Alzheimer\u2019s Disease. 2024;11(4):874\u201380.","journal-title":"J Prev Alzheimer\u2019s Disease"},{"key":"1867_CR17","doi-asserted-by":"crossref","unstructured":"Yaari R, Holdridge K, Ferguson M, Wessels A, Sims J. Decentralized approaches in TRAILBLAZER-ALZ 3 (P7-6.006). Neurology. 2023;100(17_supplement_2).","DOI":"10.1212\/WNL.0000000000202956"},{"issue":"4","key":"1867_CR18","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1002\/alz.12748","volume":"19","author":"MS Rafii","year":"2023","unstructured":"Rafii MS, Sperling RA, Donohue MC, Zhou J, Roberts C, Irizarry MC, et al. The AHEAD 3-45 study: design of a prevention trial for alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2023;19(4):1227\u201333.","journal-title":"Alzheimer\u2019s Dement"},{"issue":"2","key":"1867_CR19","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1200\/JCO.2008.21.3652","volume":"28","author":"EB Lamont","year":"2010","unstructured":"Lamont EB, Landrum MB, Keating NL, Archer L, Lan L, Strauss GM, et al. Differences in clinical trial patient attributes and outcomes according to enrollment setting. J Clin Oncol. 2010;28(2):215\u201321.","journal-title":"J Clin Oncol"},{"key":"1867_CR20","unstructured":"U.S. Census Bureau. Census Bureau releases new educational attainment data Census.gov.: US Census Bureau; 2023 [updated 2\/16\/2023. Available from: https:\/\/www.census.gov\/newsroom\/press-releases\/2023\/educational-attainment-data.html"},{"key":"1867_CR21","doi-asserted-by":"crossref","unstructured":"Arce Renter\u00eda M, Mobley TM, Evangelista ND, Medina LD, Deters KD, Fox-Fuller JT et al. Representativeness of samples enrolled in Alzheimer\u2019s disease research centers. Alzheimer\u2019s & Dementia: Diagnosis, Assessment & Disease Monitoring. 2023;15(2).","DOI":"10.1002\/dad2.12450"},{"issue":"4","key":"1867_CR22","doi-asserted-by":"publisher","first-page":"242","DOI":"10.14283\/jpad.2020.31","volume":"7","author":"JB Langbaum","year":"2020","unstructured":"Langbaum JB, High N, Nichols J, Kettenhoven C, Reiman EM, Tariot PN. The alzheimer\u2019s prevention registry: A large Internet-Based participant recruitment registry to accelerate referrals to alzheimer\u2019s-Focused studies. J Prev Alzheimer\u2019s Disease. 2020;7(4):242\u201350.","journal-title":"J Prev Alzheimer\u2019s Disease"},{"issue":"1","key":"1867_CR23","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1097\/WAD.0000000000000368","volume":"35","author":"A Gombosev","year":"2021","unstructured":"Gombosev A, Salazar CR, Hoang D, Cox CG, Gillen DL, Grill JD. Direct mail recruitment to a potential participant registry. Alzheimer Disease Assoc Disorders. 2021;35(1):80\u20133.","journal-title":"Alzheimer Disease Assoc Disorders"},{"issue":"4","key":"1867_CR24","doi-asserted-by":"publisher","first-page":"219","DOI":"10.14283\/jpad.2020.46","volume":"7","author":"S Walter","year":"2020","unstructured":"Walter S, Clanton TB, Langford OG, Rafii MS, Shaffer EJ, Grill JD, et al. Recruitment into the alzheimer prevention trials (APT) webstudy for a Trial-Ready cohort for preclinical and prodromal alzheimer\u2019s disease (TRC-PAD). J Prev Alzheimer\u2019s Disease. 2020;7(4):219\u201325.","journal-title":"J Prev Alzheimer\u2019s Disease"},{"issue":"12","key":"1867_CR25","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1016\/j.jalz.2019.07.015","volume":"15","author":"CE Gleason","year":"2019","unstructured":"Gleason CE, Norton D, Zuelsdorff M, Benton SF, Wyman MF, Nystrom N, et al. Association between enrollment factors and incident cognitive impairment in Blacks and whites: data from the alzheimer\u2019s disease center. Alzheimer\u2019s Dement. 2019;15(12):1533\u201345.","journal-title":"Alzheimer\u2019s Dement"},{"key":"1867_CR26","unstructured":"Early Alzheimer\u2019s Disease: Developing Drugs for Treatment \u2013 Guidance for Industry. U.S. Food and Drug Administration. 2018 [Available from: https:\/\/www.fda.gov\/media\/110903\/download"},{"issue":"7","key":"1867_CR27","doi-asserted-by":"publisher","first-page":"e2114364","DOI":"10.1001\/jamanetworkopen.2021.14364","volume":"4","author":"R Raman","year":"2021","unstructured":"Raman R, Quiroz YT, Langford O, Choi J, Ritchie M, Baumgartner M, et al. Disparities by race and ethnicity among adults recruited for a preclinical alzheimer disease trial. JAMA Netw Open. 2021;4(7):e2114364.","journal-title":"JAMA Netw Open"},{"issue":"23","key":"1867_CR28","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1056\/NEJMoa050151","volume":"352","author":"RC Petersen","year":"2005","unstructured":"Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005;352(23):2379\u201388.","journal-title":"N Engl J Med"},{"issue":"1","key":"1867_CR29","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1097\/JCP.0b013e31823f3b47","volume":"32","author":"CM Dording","year":"2012","unstructured":"Dording CM, Dalton ED, Pencina MJ, Fava M, Mischoulon D. Comparison of academic and nonacademic sites in Multi-Center clinical trials. J Clin Psychopharmacol. 2012;32(1):65\u20138.","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"1867_CR30","doi-asserted-by":"publisher","first-page":"3827","DOI":"10.1002\/alz.13803","volume":"20","author":"DP Molina-Henry","year":"2024","unstructured":"Molina-Henry DP, Raman R, Liu A, Langford O, Johnson K, Shum LK, et al. Racial and ethnic differences in plasma biomarker eligibility for a preclinical alzheimer\u2019s disease trial. Alzheimer\u2019s Dement. 2024;20(6):3827\u201338.","journal-title":"Alzheimer\u2019s Dement"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01867-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-025-01867-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01867-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T01:03:21Z","timestamp":1760490201000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-025-01867-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1867"],"URL":"https:\/\/doi.org\/10.1186\/s13195-025-01867-8","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,14]]},"assertion":[{"value":"19 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The A4 Study was conducted in accordance with International Council for Harmonisation Good Clinical Practice guidelines. Each A4 site obtained approval from their local institutional review board. The participants screening for the A4 Study provided permission to share their de-identified data to permit secondary analyses such as those in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Participants in A4 provided consent for the publication of de-identified data, such as those reported in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MCD\u2019s spouse is a fulltime employee of Janssen Pharmaceuticals. RAS has served as a consultant for AbbVie, AC Immune, Acumen, Alector, Apellis, Biohaven, Bristol Myers Squibb, Genentech, Ionis, Janssen, Oligomerix, Prothena, Roche, and Vaxxinity over the past 3 years. She has received research funding from Eisai and Eli Lilly for public-private partnership clinical trials and receives research grant funding from the National Institute on Aging\/National Institutes of Health, GHR Foundation, and the Alzheimer\u2019s Association. Her spouse, K. Johnson, reports consulting fees from Novartis, Merck, and Janssen. Other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"222"}}